NCT06096142招募中不适用
Prospective, Randomized, Controlled, Multicenter Study of the Solaris DE Endoprosthesis in the Treatment of Venous Outflow Stenosis or Occlusion in Hemodialysis Patients
Scitech Produtos Medicos SA5 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2024年8月30日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 120
- 试验地点
- 5
- 主要终点
- Safety Events
研究概览
简要总结
The goal of this clinical trial is to demonstrate the safety and efficacy of Solaris DE Endoprosthesis in the treatment of stenosis or occlusion within the outflow circuit of the dialysis access including arteriovenous (AV) fistula and synthetic AV graft.
Participants will be treated with Solaris DE Endoprosthesis. Researchers will compare the treatment with investigational product to Percutaneous Transluminal Angioplasty (PTA) alone within the AV fistula cohort in order to demonstrate superiority of Solaris DE.
详细描述
This is a prospective, randomized (1:1), controlled, multicenter study to investigate the safety and efficacy of the Solaris DE Endoprosthesis in the treatment of hemodialysis patients with stenosis or occlusion of the venous outflow circuit. The study population includes two cohorts:
- AVF cohort: participants presenting an arteriovenous fistula (AVF) stenosis or occlusion of the peripheral venous outflow circuit, including the cephalic arch, will be randomized 1:1 between treatment with the test device (Solaris DE) or standard treatment by Percutaneous Transluminal Angioplasty (PTA) alone);
- AVG cohort: participants with an arteriovenous graft (AVG) presenting stenosis or occlusion at the graft vein anastomosis or juxta-anastomosis or at the segment of the prosthesis exit circuit, will be treated with the test device (Solaris DE) only.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant has a mature AV Fistula (AVF) or Graft (AVG) in the arm created ≥ 30 days before the initial procedure and is in use for dialysis therapy
- •The participant has clinical and/or hemodynamic evidence of a venous outflow obstruction or AV fistula or graft dysfunction. The stenotic lesion is ≥ 50%, with a maximum length of 8 cm and a distal reference vessel diameter from 4.0 mm to 9.0 mm
- •The participan provides written informed consent prior to any study-specific procedure
- •The participan is willing to undergo all follow-up evaluations according to the specified schedule over 24 months
- •Angiographic Inclusion Criteria:
- •The target lesion originates ≥ 3 cm from the cannulation segment (needling zone)
- •The target lesion is located:
- •In one arm (including the cephalic arch) in a participant with AVF, and not in the cannulation segment, OR
- •In the anastomosis or juxta-anastomosis in a participant with AVF (a juxta-anastomosis is defined as a location where the stent crosses the venous anastomosis)
- •The target lesion includes a de novo stenotic lesion or restenosis
- •The target lesion is ≥ 5 cm from the arterial anastomosis
- •The target lesion has ≥ 50% stenosis according to the operator's visual judgment
- •The distal reference vessel diameter of the target lesion is between 4.0 mm and 9.0 mm by the operator's visual judgment
- •Single or multiple target lesions measuring ≤ 8 cm in total length by the operator's visual judgment
- •Single or multiple target lesions should be covered by a single stent or multiple overlapping stents, provided they are treated as a single lesion with a maximum length of 8 cm
- •Successful target lesion pre-dilatation is defined as crossover of the guidewir resulting in full expansion of the pre-dilatation balloon
- •The participant has up to 1 (one) non-target lesion in the access circuit requiring intervention in the initial procedure. The non-target lesion must be at least 10 cm away from the target lesion. The non-target lesion can only be treated with standard PTA alone
- •Does not have stent implanted or it has been in the access circuit for ≥ 30 days since placement and patent with ≤ 30% stenosis and located ≥ 5 cm from the target lesion
- •The non-target lesion must be successfully treated at the time of the initial procedure (success measured as ≤30% residual stenosis and no complications).
排除标准
- •Pregnant, breastfeeding or with intention to become pregnant in the next year
- •The participant has any major endovascular or surgical procedure planned (including in the access circuit) within 30 days of the initial procedure
- •It was not possible to pre-dilate the lesion to be treated with Solaris DE
- •Planned surgical revision of the access site
- •Known or suspected infection of the hemodialysis access site, systemic infection and/or sepsis
- •Patients on immunosuppressive therapy
- •Known active coagulopathy or bleeding diathesis
- •Known hypersensitivity to nickel titanium alloy, contrast or sirolimus
- •Contraindication to antiplatelet, anticoagulant or thrombolytic therapies
- •Known allergy to contrast agents or medications administered to perform endovascular intervention that cannot be adequately premedicated
- •Life expectancy of less than 12 months
- •Has a stent or endoprosthesis located anywhere in the AV access circuit that is not patent (> 30% stenosis) or implanted < 30 days
- •The participant's hemodialysis access is expected to be abandoned within 6 months
- •The participantis is enrolled in another trial involving an investigational product (pharmaceutical, biological or medical device)
- •The patient has a permanent central venous catheter (CVC) for dialysis access, except when its use is temporary, as a bridge to treatment through the access circuit, with a plan for removal after a successful dialysis session after the initial procedure
- •Angiographic Exclusion Criteria:
- •The target lesion is located inside an endoprosthesis
- •Target lesion treatment would involve the cannulation segment (needling zone)
- •The target lesion is < 5 cm from the arterial anastomosis
- •There was a dissection or rupture of the treated vessel during the initial treatment that could not be controlled
- •Evidence of an aneurysm, pseudoaneurysm or acute thrombus (i.e. one that has been treated ≤ 15 days) within the target lesion
- •The target lesion is, and/or Solaris DE would be placed anywhere:
- •Through the elbow
- •In a region that causes bending of the endoprosthesis or bony protrusion over it
- •In the cannulation segment (needling zone)
- •Inside any part of a pre-existing stent or endoprosthesis (apart from an access arteriovenous graft)
- •Lower extremity
- •Non-synthetic graft
- •Central thoracic veins located proximal to the cephalic vein arch
- •The target lesion is located in such a way that the insertion of a stent would result in a "kink" area that requires a stent bridge between the Solaris DE and an existing stent or stent graft
- •The individual has more than 1 (one) non-target lesion (≥ 50% stenosis) that requires intervention in the initial procedure
研究组 & 干预措施
AVF Control
Sham Comparator
Participants on dialysis via AV fistula will be treated with percutaneous transluminal angioplasty (PTA) alone.
干预措施: PTA (Device)
AVF Treatment
Experimental
Participants on dialysis via AV fistula will be treated with percutaneous transluminal angioplasty (PTA) followed by Solaris DE implantation.
干预措施: Solaris DE (Device)
AVG Treatment
Experimental
Participants on dialysis via AV graft will be treated with percutaneous transluminal angioplasty (PTA) followed by Solaris DE implantation.
干预措施: Solaris DE (Device)
结局指标
主要结局
Safety Events
时间窗: 30 days
Percentage of participants without any safety events affecting the access or venous outflow circuit and resulting in new intervention, hospitalization or death (not including stenosis or thrombosis).
Target Lesion Primary Patency (TLPP)
时间窗: 6 months
Percentage of participants without restenosis or clinically indicated target lesion revascularization or thrombosis.
次要结局
- Target Lesion Primary Patency (TLPP)(12 and 24 months)
- Cumulative Patency (CP)(1, 6, 12 and 24 months)
- Access Circuit Primary Patency (ACPP)(1, 6, 12 and 24 months)
- Assisted Target Lesion Primary Patency (aTLPP)(1, 6, 12 and 24 months)
- Procedure and device-related complications(1, 6, 12 and 24 months)
研究者
研究点 (5)
Loading locations...
相似试验
尚未招募
不适用
Orthopedic Intelligent Navigation System in the Treatment of Fresh Femoral Neck FracturesFracture of Neck of FemurNCT06713018Chinese PLA General Hospital300
终止
2 期
Study of Occipital Nerve Stimulation for Drug Refractory MigraineMigraineNCT00747812Boston Scientific Corporation11
已完成
不适用
STELLA® Endogastric Balloon System. Evaluation of Safety and Introduction System at 7 Months.Overweight/ObesityNCT06744829Mikromic Medical, S. L69
已完成
不适用
Software-delivered CBT-I for Insomnia DisorderInsomnia DisorderNCT05747963Peking University Sixth Hospital236
招募中
不适用
Study on the Efficacy and Safety of Rechargeable Implantable DBS System in the Treatment of Parkinson's DiseaseParkinson DiseaseNCT05997667Lepu Medical Technology (Beijing) Co., Ltd.60